stockportfolio.pro
Stocks / CORT vs IBRX
CORT vs IBRX
Corcept Therapeutics Incorporated and ImmunityBio, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Corcept Therapeutics Incorporated (CORT) | ImmunityBio, Inc. (IBRX) | |
|---|---|---|
| Market cap | $8.4B | $7.5B |
| Revenue (latest FY) | $761.41M | $113.29M |
| Net income (latest FY) | $98.17M | $-351.40M |
| Revenue growth (5y CAGR) | 16.6% | 184.8% |
| Net margin | 12.9% | -310.2% |
| Return on equity | 15.2% | 70.2% |
| P/E ratio | 222.6 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 10 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CORT — free Open IBRX — freeFrequently asked questions
Which is bigger, CORT or IBRX?
Corcept Therapeutics Incorporated is larger by market capitalization — $8.4B versus $7.5B.
Which grows faster, CORT or IBRX?
Over the last five fiscal years, ImmunityBio, Inc. grew revenue faster — 184.8%/yr versus 16.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.